Delcath Systems

Expanded Clinical Trials And Program Integration Will Define Oncology's Future

AnalystConsensusTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

02 May 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$24.33

57.4% undervalued

15 Aug

US$10.36

38.1%

3.5%

Author's Valuation

US$24.3

57.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$24.3

57.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

23.23%

Medical Equipment revenue growth rate

0.45%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.48%

Calculation

US$89.21m

Earnings '28

23.10x

PE Ratio '28

US$2.06b

Market Cap '28

US$2.06b

Market Cap '28

68.22m

No. shares '28

US$30.22

Share Price '28

US$30.22 Share Price '28

Discounted to 2025 @ 7.48% p.a.

US$24.33

Fair Value '25